Submitted for your consideration:
ADT is a difficult part of treatment for intermediate and high risk prostate cancer. Apparently there has been a trend for those having primary external beam radiation therapy (EBRT) to replace ADT with a brachytherapy (BT) boost.
This study, published May 12, 2020, is a retrospective meta-study, a "study of studies". As with all such studies it has some inherent bias issues such as patient selection and so on. They did only include randomized trials, which helps. I have only found the abstract, but this looks like it would be an interesting one to review. (Note, it is not specifically addressing a closely related question of EBRT+ADT+BT, vs. EBRT+ADT. That's a different question.)
Given that caveat, it is an interesting conclusion.Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials
From the article:Conclusion: Our findings suggest that current practice patterns of omitting ADT with EBRT plus BT may result in inferior OS compared with EBRT plus ADT in men with intermediate- and high-risk prostate cancer. ADT for these men should remain a critical component of treatment regardless of radiotherapy delivery method until randomized evidence demonstrates otherwise.